Fiscal 2024 net revenue of $159.8 million 17.6% year-over-year growth in Organigram's recreational shipped sales in Fiscal 2024 Q4 Fiscal 2024 adjusted gross margin1 of 37% Q4 Fiscal 2024 adjusted EBITDA2 of $5.9 million or 13% of net revenue Q4 Fiscal 2024 cash flow from operations of $8.9 million Became Canada's largest cannabis company by market share following the acquisition of Motif Labs subsequent to year end Organigram Holdings Inc. (NASDAQ:OGI) (TSX:OGI), (the "Company" or "Organigram"), a leading licensed producer ("LP") of cannabis, announced its results for the fourth quarter and twelve months ended September 30, 2024 ("Q4 Fiscal 2024" or "Fiscal 2024"). All f

Organigram Holdings Inc. (NASDAQ:OGI) (TSX:OGI), the parent company of Organigram Inc. (together, the "Company" or "Organigram"), a leading licensed producer of cannabis, announced today it will report earnings results for its fourth quarter and fiscal 2024 ended September 30, 2024, on Wednesday, December 18, 2024, prior to market open. The Company will host a conference call to discuss its results with details as follows: Date: Wednesday, December 18, 2024 Time: 8:00 am Eastern Time To register for the conference call, please use this link: https://registrations.events/direct/Q4I96766465 To ensure you are connected for the full call, we suggest registering a day in advance or at mi

Transformational Acquisition Results in Cannabis Pure Play Leader, Coast-to-Coast Geographic Strength and Proven Excellence in Consumer-Focused Innovation, Cultivation, Product Development, Extraction and Manufacturing Combination results in #1 market share position in the Canadian recreational cannabis market1 Catapults Organigram into the #1 position in the vape category and accelerates the Company's market share in the fast-growing infused pre-roll segment1 Strong brand portfolio now anchored by Organigram's "SHRED" and Motif's "BOXHOT" - two of Canada's beloved cannabis brands Highly complementary product portfolios with expanded geographic reach Organigram gains strategi

Company Continues to Lead in Innovation with Launch of Edison Sonics Gummies Featuring Groundbreaking FAST™ Nanoemulsion Technology Clinically Proven to Deliver up to ~50% Faster Onset, Improved Bioavailability and Nearly Double the Cannabinoid Delivery at Peak Effect Organigram Holdings Inc. (NASDAQ:OGI) (TSX:OGI), (the "Company" or "Organigram"), a leading licensed producer of cannabis, is thrilled to finally launch Edison Sonics gummies, Organigram's inaugural product powered by FAST™, the Company's groundbreaking nanoemulsion technology and a first-to-market innovation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/202

Organigram Holdings Inc. (NASDAQ:OGI) (TSX:OGI), (the "Company" or "Organigram"), a leading licensed producer of cannabis, announced today that on August 30, 2024, the Company closed the second of three tranches (the "Second Tranche") of the previously announced C$124,559,674 follow-on strategic equity investment (the "Investment") by BT DE Investments Inc. (the "Investor"), a wholly owned subsidiary of British American Tobacco plc ("BAT"). Pursuant to the Second Tranche closing, the Investor acquired 4,429,740 common shares (the "Common Shares") and 8,463,435 Class A preferred shares (the "Preferred Shares" and together with the Common Shares, the "Shares") of the Company at a price of C$3

Net revenue of $41.1 million increased 25% over the prior year period Adjusted EBITDA1 of $3.5 million versus $(2.9) million over the prior year period Established European foothold with a strategic investment in Sanity Group, a leading German cannabis company Completed landmark clinical study on FAST™ nanoemulsion technology showing faster onset, improved bioavailability of ingestible products Pro-forma cash position of $173 million2 Organigram Holdings Inc. (NASDAQ:OGI) (TSX:OGI), (the "Company" or "Organigram"), a leading licensed producer of cannabis, announced its results for the third quarter ended June 30, 2024 ("Q3 Fiscal 2024"). THIRD QUARTER HIGHLIGHTS Third q

FAST™ Nanoemulsion Technology Expected to be a Competitive Advantage for Organigram's Ingestible Portfolio Organigram Holdings Inc. (NASDAQ:OGI) (TSX:OGI), a leading licensed producer of cannabis, is pleased to unveil the preliminary results of its landmark clinical pharmacokinetic (PK) study conducted via the Product Development Collaboration (PDC) on its latest innovation, nanoemulsion technology. This patent-pending technology, branded FAST™ (Fast Acting Soluble Technology), will be the first innovation to be commercialized by Organigram leveraging the output of the PDC*, a "Center of Excellence" established to focus on developing next-generation cannabis products. The clinical study

Organigram Holdings Inc. (NASDAQ:OGI) (TSX:OGI), the parent company of Organigram Inc. (together, the "Company" or "Organigram"), a leading licensed producer of cannabis, announced today it will report earnings results for its third quarter fiscal 2024 ended June 30, 2024, on Tuesday, August 13, 2024, prior to market open. The Company will host a conference call to discuss its results with details as follows: Date: Tuesday, August 13, 2024 Time: 8:00 am Eastern Time To register for the conference call, please use this link: https://registrations.events/direct/Q4I9676663358 To ensure you are connected for the full call, we suggest registering a day in advance or at minimum 10 minutes

Organigram Holdings Inc. (NASDAQ:OGI) (TSX:OGI), (the "Company" or "Organigram"), a leading licensed producer of cannabis, announced the appointment of Craig Harris to the Organigram Board of Directors effective today. Craig brings over 20 years of experience as a commercial lawyer, with a background in private practice and legal and regulatory engagement roles for various corporations. He is currently the Assistant General Counsel – Corporate & Commercial Legal at British American Tobacco plc (BAT). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240729497569/en/Craig Harris (Photo: Business Wire) "We are thrilled to welcome Cra

The partial third tranche investment is expected to enable Organigram to expand its product portfolio, addressing consumer demand for unique and differentiated aromas and flavours. This strategic funding supports the growth and diversification of Organigram's offerings with a view to enhancing its market position and appeal to consumers. Already a cultivation leader in high THCV cultivars, Organigram will now pilot higher potency rare cannabinoids such as CBG, CBC and CBDV. Organigram Holdings Inc. (NASDAQ:OGI) (TSX:OGI), (the "Company" or "Organigram"), a leading licensed producer of cannabis, announced today that it has completed an early partial funding of its final third tranc

Fiscal 2024 net revenue of $159.8 million 17.6% year-over-year growth in Organigram's recreational shipped sales in Fiscal 2024 Q4 Fiscal 2024 adjusted gross margin1 of 37% Q4 Fiscal 2024 adjusted EBITDA2 of $5.9 million or 13% of net revenue Q4 Fiscal 2024 cash flow from operations of $8.9 million Became Canada's largest cannabis company by market share following the acquisition of Motif Labs subsequent to year end Organigram Holdings Inc. (NASDAQ:OGI) (TSX:OGI), (the "Company" or "Organigram"), a leading licensed producer ("LP") of cannabis, announced its results for the fourth quarter and twelve months ended September 30, 2024 ("Q4 Fiscal 2024" or "Fiscal 2024"). All f

Organigram Holdings Inc. (NASDAQ:OGI) (TSX:OGI), the parent company of Organigram Inc. (together, the "Company" or "Organigram"), a leading licensed producer of cannabis, announced today it will report earnings results for its fourth quarter and fiscal 2024 ended September 30, 2024, on Wednesday, December 18, 2024, prior to market open. The Company will host a conference call to discuss its results with details as follows: Date: Wednesday, December 18, 2024 Time: 8:00 am Eastern Time To register for the conference call, please use this link: https://registrations.events/direct/Q4I96766465 To ensure you are connected for the full call, we suggest registering a day in advance or at mi

Transformational Acquisition Results in Cannabis Pure Play Leader, Coast-to-Coast Geographic Strength and Proven Excellence in Consumer-Focused Innovation, Cultivation, Product Development, Extraction and Manufacturing Combination results in #1 market share position in the Canadian recreational cannabis market1 Catapults Organigram into the #1 position in the vape category and accelerates the Company's market share in the fast-growing infused pre-roll segment1 Strong brand portfolio now anchored by Organigram's "SHRED" and Motif's "BOXHOT" - two of Canada's beloved cannabis brands Highly complementary product portfolios with expanded geographic reach Organigram gains strategi

Net revenue of $41.1 million increased 25% over the prior year period Adjusted EBITDA1 of $3.5 million versus $(2.9) million over the prior year period Established European foothold with a strategic investment in Sanity Group, a leading German cannabis company Completed landmark clinical study on FAST™ nanoemulsion technology showing faster onset, improved bioavailability of ingestible products Pro-forma cash position of $173 million2 Organigram Holdings Inc. (NASDAQ:OGI) (TSX:OGI), (the "Company" or "Organigram"), a leading licensed producer of cannabis, announced its results for the third quarter ended June 30, 2024 ("Q3 Fiscal 2024"). THIRD QUARTER HIGHLIGHTS Third q

Organigram Holdings Inc. (NASDAQ:OGI) (TSX:OGI), the parent company of Organigram Inc. (together, the "Company" or "Organigram"), a leading licensed producer of cannabis, announced today it will report earnings results for its third quarter fiscal 2024 ended June 30, 2024, on Tuesday, August 13, 2024, prior to market open. The Company will host a conference call to discuss its results with details as follows: Date: Tuesday, August 13, 2024 Time: 8:00 am Eastern Time To register for the conference call, please use this link: https://registrations.events/direct/Q4I9676663358 To ensure you are connected for the full call, we suggest registering a day in advance or at minimum 10 minutes

21% growth in recreational net revenue year-over-year First Jupiter private placement tranche closed adding $41.5 million of cash bringing Organigram's closing cash balance at quarter-end to $83.6 million Subsequent to quarter end, closed $28.8 million oversubscribed marketed offering, which when combined with the remaining two anticipated Jupiter tranches will increase cash position by additional $110 million Company's recent investment in Steady State LLC (d/b/a Open Book Extracts) ("OBX") adds to growing U.S. portfolio, which includes Phylos Bioscience Inc. ("Phylos") Organigram's U.S.-based strategic investments may benefit from expected change in rescheduling of cannabis b

Organigram Holdings Inc. (NASDAQ:OGI) (TSX:OGI), the parent company of Organigram Inc. (together, the "Company" or "Organigram"), a leading licensed producer of cannabis, announced today it will report earnings results for its second quarter fiscal 2024 ended March 31, 2024, on Tuesday, May 14, 2024, prior to market open. The Company will host a conference call to discuss its results with details as follows: Date: Tuesday, May 14, 2024 Time: 8:00 am Eastern Time To register for the conference call, please use this link: https://registrations.events/direct/Q4I9676693302 To ensure you are connected for the full call, we suggest registering a day in advance or at minimum 10 minutes bef

Achieved positive cash flow from operations, solidified #2 market position in Canada among licensed producers, significantly improved margins sequentially quarter-over-quarter, and closed first $41.5 million tranche of previously announced $124.6 million investment from BAT HIGHLIGHTS $124.6 million strategic investment from BAT announced in November 2023 approved by shareholders, with first of three tranches now funded at $3.22 per share for proceeds of $41.5 million Achieved positive Adjusted EBITDA1 and positive cash flow from operations of $7.7 million Improved sequential quarter-over-quarter adjusted gross margin2 from 17% in Q4 Fiscal 2023 (references to "Fiscal 2023" are t

Organigram Holdings Inc. (NASDAQ:OGI) (TSX:OGI), the parent company of Organigram Inc. (together, the "Company" or "Organigram"), a leading licensed producer of cannabis, announced today it will report earnings results for its first quarter fiscal 2024 ended December 31, 2023, on Tuesday, February 13, 2024, prior to market open. The Company will host a conference call to discuss its results with details as follows: Date: Tuesday, February 13, 2024 Time: 8:00 am Eastern Time To register for the conference call, please use this link: https://registrations.events/direct/Q4I967666846597333509997000 To ensure you are connected for the full call, we suggest registering a day in advance or

Domestic share growth in several key categories continues to be driven by innovation excellence and industry-leading R&D. Organigram continues to take a leadership position in industry fighting THC mislabelling (inflation). Company fortifying itself with recently announced BAT-Jupiter $124.6 million private placement transaction strengthening balance sheet and setting the stage for long-term growth outside of Canada. FISCAL 2023 HIGHLIGHTS At year-end, achieved the #2 position among Canadian licensed producers driven by success of growing pre-roll business2 Held the #1 position in the milled flower, gummies, and hash categories2 Held the #3 market position in Ontario, #3

40-F/A - ORGANIGRAM HOLDINGS INC. (0001620737) (Filer)

40-F - ORGANIGRAM HOLDINGS INC. (0001620737) (Filer)

6-K - ORGANIGRAM HOLDINGS INC. (0001620737) (Filer)

6-K - ORGANIGRAM HOLDINGS INC. (0001620737) (Filer)

6-K - ORGANIGRAM HOLDINGS INC. (0001620737) (Filer)

6-K - ORGANIGRAM HOLDINGS INC. (0001620737) (Filer)

6-K - ORGANIGRAM HOLDINGS INC. (0001620737) (Filer)

6-K - ORGANIGRAM HOLDINGS INC. (0001620737) (Filer)

6-K - ORGANIGRAM HOLDINGS INC. (0001620737) (Filer)

6-K - ORGANIGRAM HOLDINGS INC. (0001620737) (Filer)

Canaccord Genuity resumed coverage of OrganiGram with a rating of Speculative Buy

Alliance Global Partners upgraded OrganiGram from Neutral to Buy

Stifel upgraded OrganiGram from Hold to Buy

Canaccord Genuity upgraded OrganiGram from Hold to Speculative Buy

Cantor Fitzgerald reiterated coverage of OrganiGram Holdings with a rating of Overweight and set a new price target of $5.30 from $5.70 previously

Cantor Fitzgerald reiterated coverage of OrganiGram Holdings with a rating of Overweight and set a new price target of $5.70 from $5.50 previously

CIBC upgraded OrganiGram from Sector Underperform to Neutral

CIBC downgraded OrganiGram from Neutral to Sector Underperform

CIBC downgraded OrganiGram Holdings from Neutral to Underperformer and set a new price target of $3.25 from $5.00 previously

CIBC downgraded OrganiGram Holdings from Neutral to Underperform and set a new price target of $3.25 from $5.00 previously

SC 13D/A - ORGANIGRAM HOLDINGS INC. (0001620737) (Subject)

SC 13D/A - ORGANIGRAM HOLDINGS INC. (0001620737) (Subject)

SC 13D/A - ORGANIGRAM HOLDINGS INC. (0001620737) (Subject)

SC 13D/A - ORGANIGRAM HOLDINGS INC. (0001620737) (Subject)

SC 13D/A - ORGANIGRAM HOLDINGS INC. (0001620737) (Subject)

SC 13G/A - ORGANIGRAM HOLDINGS INC. (0001620737) (Subject)

SC 13G/A - ORGANIGRAM HOLDINGS INC. (0001620737) (Subject)

SC 13D - ORGANIGRAM HOLDINGS INC. (0001620737) (Subject)

SC 13G/A - ORGANIGRAM HOLDINGS INC. (0001620737) (Subject)

Organigram Holdings Inc. (NASDAQ:OGI) (TSX:OGI), (the "Company" or "Organigram"), a leading licensed producer of cannabis, announced the appointment of Craig Harris to the Organigram Board of Directors effective today. Craig brings over 20 years of experience as a commercial lawyer, with a background in private practice and legal and regulatory engagement roles for various corporations. He is currently the Assistant General Counsel – Corporate & Commercial Legal at British American Tobacco plc (BAT). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240729497569/en/Craig Harris (Photo: Business Wire) "We are thrilled to welcome Cra

Organigram Holdings Inc. ("Organigram" or the "Company") (TSX:OGI) (NASDAQ:OGI), announced the appointment of Karina Gehring to the Organigram Board of Directors at the Company's annual general and special meeting held on January 18, 2024. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240119151071/en/Karina Gehring (Photo: Business Wire) "We are thrilled to welcome Karina to our Board of Directors. Her extensive expertise in marketing and brand management combined with her ongoing experience with BAT will be a tremendous asset to our Board," said Peter Amirault, Board Chair, Organigram. Karina is one of two directors (includi

Organigram Holdings Inc. ("Organigram" or the "Company") (TSX:OGI) (NASDAQ:OGI) announced today the results of voting at its annual general and special meeting of shareholders (the "Shareholders") held virtually on January 18, 2024 (the "Meeting"). Election of Directors Each of the nine nominees listed in the Company's management information circular dated December 20, 2023 (the "Circular") provided in connection with the Meeting were elected as directors of the Company. The Company received proxies and virtual votes at the Meeting as set out below: Nominee # Votes For % of Votes For # Votes Against % of Votes Against Peter Amirault 21,048,219

Special Meeting to Approve $124.6 Million Investment from BAT at $3.2203/share and Creation of "Jupiter" Strategic Investment Pool Organigram Holdings Inc. (NASDAQ:OGI) (TSX:OGI), (the "Company" or "Organigram"), a leading licensed producer of cannabis, announced today that it has mailed and filed a management information circular (the "Circular") and related materials (the "Meeting Materials") for its annual and special meeting (the "Meeting") of the holders of its common shares (the "Shareholders") to be held on January 18, 2024. In addition to routine annual business to be conducted (including the election of directors and the appointment of an auditor), Shareholders at the Meeting wil

Organigram Holdings Inc. ("Organigram" or the "Company") (TSX:OGI) (NASDAQ:OGI) is pleased to announce that Greg Guyatt CPA, CA, formerly of Phoena Holdings Inc. ("Phoena"), has been appointed to the role of Chief Financial Officer effective January 8, 2024. Mr. Guyatt will lead Organigram's Finance and IT divisions and will report directly to Beena Goldenberg, Organigram's Chief Executive Officer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231218771633/en/Greg Guyatt (Photo: Business Wire) Mr. Guyatt is a seasoned financial executive with over 25 years of international public company and private equity backed company experi

Organigram Holdings Inc. (NASDAQ:OGI) (TSX:OGI), (the "Company" or "Organigram"), a leading licensed producer of cannabis, announces today that Ms. Caroline Ferland has resigned from the Board of Directors ("the Board") effective immediately. Ms. Ferland was a board member nominee appointed by BAT. "In her short time on the Board, Ms. Ferland made considerable contributions to Organigram," said Peter Amirault, Chair of Organigram's Board of Directors. "In addition to providing meaningful involvement on the strategic planning and corporate governance fronts, Ms. Ferland used her extensive international experience in legal and regulatory matters to support the Company, providing solid strat

FN Media Group Presents Microsmallcap.com Market Commentary NEW YORK, Aug. 23, 2022 /PRNewswire/ -- The CBD oil market is expected to witness an astounding CAGR of 38.90% from 2021 until 2029, climbing from $9.86 billion to $136.64 billion. There are several reasons behind the projected growth such a growing number of CBD-infused skincare products, increased use of THC and CBD in pain management and treatment, rising sales in both retail stores and online, expanding research, and increasing demand for ingestible products. Governments around the world have also begun opening up more doors for CBD, with a recent Health Canada report suggesting legal framework to broaden retail CBD sales across

Organigram Holdings Inc. ("Organigram" or the "Company") (TSX:OGI) (NASDAQ:OGI), the parent company of Organigram Inc., a leading Canadian producer of cannabis, is pleased to announce Beena Goldenberg, formerly Chief Executive Officer of The Supreme Cannabis Company Inc. and previously Chief Executive Officer at Hain-Celestial Canada, ULC, has been appointed the Company's new Chief Executive Officer (CEO). Ms. Goldenberg will assume the role effective September 9, 2021. An accomplished business leader, Ms. Goldenberg has more than 30 years of experience in consumer-packaged goods, manufacturing and marketing. As President and CEO of The Supreme Cannabis Company Inc., she successfully achie

Organigram Holdings Inc. ("Organigram" or the "Company") (TSX:OGI) (NASDAQ:OGI), the parent company of Organigram Inc., a leading producer of cannabis, is pleased to announce the appointment of Megan McCrae as the Company's Senior Vice President of Marketing and Communications. Ms. McCrae will assume her new role effective today. A seasoned marketing expert, Ms. McCrae has 17 years experience in consumer packaged goods marketing and sales management, brand building and consumer insights. Ms. McCrae is a cannabis industry veteran, having most recently served as Chief Marketing Officer of Aphria Inc. where she led the company's brand and product strategy including brand and portfolio manage

Organigram Holdings Inc. ("Organigram" or the "Company") (TSX:OGI) (NASDAQ:OGI), the parent company of Organigram Inc., a leading producer of cannabis, is pleased to announce the appointment of Borna Zlamalik as the Company's Vice President of Innovation. Mr. Zlamalik will assume his new role effective today. In his new role, Mr. Zlamalik will draw upon his international expertise in cannabis and cannabinoid-based product advancement, commercialization, and pricing strategy to direct consumer product innovation. As the Company's Vice President, Innovation, Mr. Zlamalik will oversee all R&D and product development. He will also sit as one of Organigram's representatives on the Steering Comm